1994 Mar;16(3):299-305
For type 2 diabetes , NICE guideline NG28 recommends GLP-1 receptor agonists in specific circumstances, including: As part of triple therapy (with metformin and either a sulfonylurea or pioglitazone) when dual therapy with metformin and another oral drug has not achieved adequate glycaemic control As part of triple therapy with metformin and a sodium-glucose cotransporter 2 (SGLT2) inhibitor if certain criteria are met In combination with insulin, with or without other antidiabetic drugs Treatment should be continued only if there is a beneficial metabolic response (reduction of at least 11 mmol/mol in HbA1c and weight loss of at least 3% at 6 months)
And if so, how might these drugs be causing these side effects
With this in mind, we see the following two promising avenues as deserving increased focus going forward: (1) therapies aimed at inducing tolerance to beta cell antigens
Supporting muscle and nerve function: Beyond tendons and ligaments, research suggests that BPC-157 may stabilize the junctions between nerves and muscles, preserve acetylcholine receptors (the chemical messengers at nerve-muscle connections), and enhance muscle regeneration while reducing scar tissue formation
These licenses enable us to offer a full continuum of mental health and substance use treatment services, ensuring our clients receive the comprehensive care they deserve
